Senti Biosciences, Inc. (SNTI)

Senti Biosciences' stock price has declined significantly in the past six months. The company reported its fourth-quarter and full-year 2025 financial results on March 27, 2026, which led to a 10.36% decline in SNTI shares on the day of the news. Senti Biosciences received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for SENTI-202 and reported updated positive preliminary clinical data from the ongoing Phase 1 trial of SENTI-202. The company last reported earnings on November 13, 2025, after which the stock drifted 46.5% lower.

Senti Biosciences is primarily focused on research, development, and clinical trials, and does not generate commercial revenue from approved products. Traditional demand seasonality is not applicable to Senti Biosciences at this stage of its development.

Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing cell and gene therapies using its synthetic biology platform, which engineers Gene Circuits into medicines. The company's lead program, SENTI-202, is a CAR-NK cell therapy for hematologic malignancies, and SENTI-301A is being developed for hepatocellular carcinoma. Senti Biosciences also has preclinical and partnered programs.

Senti Biosciences, Inc. is headquartered in South San Francisco, California, United States.

Senti Biosciences' brand reputation has been influenced by positive scientific advancements and challenging stock market performance. Positive clinical data and the FDA's RMAT designation for SENTI-202 have strengthened the company's reputation. However, negative market reactions to data presentations and a substantial decrease in stock value could negatively impact investor confidence.

Senti Biosciences, Inc. has a mixed ownership structure, including institutional investors, insiders, and retail investors. Institutional shareholders own approximately 21.35% to 25.70% of the stock. Celadon Partners Spv 24 is the largest individual shareholder, owning 37.19% of the company. Omid Farokhzad is another significant insider owner.